Non-Small-Cell Lung Cancer | Unmet Need | Metastatic nonsquamous NSCLC without driver mutations | US/EU5 | UNNEON0032-2021

Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the presence of molecular aberrations. While the minority of patients found positive for EGFR, ALK, BRAF, ROS1, c-MET, or RET aberrations are eligible to receive approved targeted agents, patients without driver mutations have limited treatment options. In the last decade, approval of multiple immune checkpoint inhibitors in the first-line setting has revolutionized the treatment of metastatic nonsquamous NSCLC without driver mutations. Immunotherapies such as Keytruda (Merck & Co.), Tecentriq (Roche / Genentech), Opdivo plus Yervoy (Bristol Myers Squibb), and Libtayo (Sanofi / Regeneron Pharmaceuticals) dominate the market as monotherapy and in combination with cytotoxic agents. However, a large population of patients with metastatic disease is unresponsive to immunotherapies; hence, there is a strong need for efficacious therapies in this patient setting.

QUESTIONS ANSWERED

• What are the drivers and constraints in the treatment of metastatic nonsquamous NSCLC without driver mutations?
• How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
• What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
• What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for metastatic nonsquamous NSCLC without driver mutations?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 62 U.S. medical oncologists and 30 European medical oncologists fielded in February 2022

Key companies: Merck & Co., Bristol Myers Squibb, Roche / Genentech, Sanofi / Regeneron

Key drugs: Keytruda, Tecentriq, Opdivo, Yervoy, Libtayo